These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26023044)

  • 21. Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate.
    Tanaka Y; Masumori N; Itoh N; Furuya S; Nishizawa O; Tsukamoto T
    Urology; 2001 Feb; 57(2):270-4. PubMed ID: 11182335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction.
    Aizawa N; Watanabe D; Fukuhara H; Fujimura T; Kume H; Homma Y; Igawa Y
    Neurourol Urodyn; 2018 Aug; 37(6):1897-1903. PubMed ID: 29508437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.
    Tatemichi S; Akiyama K; Kobayashi M; Yamazaki Y; Yokoyama O; Uruno T
    J Urol; 2006 Sep; 176(3):1236-41. PubMed ID: 16890732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voiding function in obese and type 2 diabetic female rats.
    Gasbarro G; Lin DL; Vurbic D; Quisno A; Kinley B; Daneshgari F; Damaser MS
    Am J Physiol Renal Physiol; 2010 Jan; 298(1):F72-7. PubMed ID: 19889955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs.
    Nagabukuro H; Okanishi S; Doi T
    Eur J Pharmacol; 2004 Jun; 494(2-3):225-32. PubMed ID: 15212979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distigmine Bromide Produces Sustained Potentiation of Guinea-Pig Urinary Bladder Motility by Inhibiting Cholinesterase Activity.
    Obara K; Chino D; Tanaka Y
    Biol Pharm Bull; 2017; 40(6):807-814. PubMed ID: 28566624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor.
    Bougas DA; Mitsogiannis IC; Mitropoulos DN; Kollaitis GC; Serafetinides EN; Giannopoulos AM
    Int Urol Nephrol; 2004; 36(4):507-12. PubMed ID: 15787326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of action for α
    Hattori T; Sugaya K
    Life Sci; 2017 Dec; 191():90-96. PubMed ID: 29032116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silodosin, an α(1A)-Adrenoceptor Antagonist, May Ameliorate Ischemia-Induced Bladder Denervation and Detrusor Dysfunction by Improving Bladder Blood Flow.
    Goi Y; Tomiyama Y; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M; Nomiya M; Yamaguchi O
    Pharmacology; 2016; 97(3-4):161-70. PubMed ID: 26828923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silodosin improves functional consequences of lower urinary tract obstruction secondary to benign prostate hypertrophy, a proof of concept study in the spontaneously hypertensive rat supplemented with testosterone.
    Assaly R; Faugeroux J; Laurin M; Compagnie S; Alexandre L; Giuliano F; Behr-Roussel D
    BMC Urol; 2020 Aug; 20(1):132. PubMed ID: 32854676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of detrusor contraction strength and micturition characteristics by intrathecal baclofen in anesthetized rats.
    Watanabe T; Perkash I; Constantinou CE
    J Urol; 1997 Jun; 157(6):2361-5. PubMed ID: 9146671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates.
    Buono R; Briganti A; Freschi M; Villa L; La Croce G; Moschini M; Benigni F; Castiglione F; Montorsi F; Hedlund P
    Eur J Pharmacol; 2014 Dec; 744():42-51. PubMed ID: 25261033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.
    Wu YJ; Dong Q; Liu LR; Wei Q
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):79-84. PubMed ID: 22986578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the selective prostacyclin receptor antagonist RO3244019 on the micturition reflex in rats.
    Cefalu JS; Zhu QM; Eggers AC; Kaan TK; Ho MJ; Jett MF; Cockayne DA; Ford AP; Nunn PA
    J Urol; 2007 Dec; 178(6):2683-8. PubMed ID: 17945281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
    Gu BJ; Ishizuka O; Igawa Y; Nishizawa O; Andersson KE
    J Urol; 2002 Apr; 167(4):1887-91. PubMed ID: 11912454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.
    Matsukawa Y; Hattori R; Sassa N; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2013 Mar; 32(3):266-70. PubMed ID: 22907775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M; Kudoh J; Homma Y; Kawabe K
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.